Nautilus Biotechnology Q3 2025 Financial Results

Nautilus Biotechnology, Inc. reported its financial results for the third quarter ended September 30, 2025. The company highlighted continued progress in processing Tau proteoform samples and development of a new broadscale assay format, with an expected early access program launch in the first half of 2026. Operating expenses decreased by 19% to $15.5 million compared to the same period last year, and the net loss was $13.6 million. Cash, cash equivalents, and investments totaled $168.5 million as of September 30, 2025. The company plans to host a conference call to discuss these results.